Sunshine Biopharma Inc. SBFM
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Sunshine Biopharma Inc. (SBFM) is a healthcare company listed in the US with a market value of about $2M. In the twelve months to September 30, 2026 it had revenue of $35M and net income of -$6M, a net margin of -17.5%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (2/5); the weakest is shareholder returns (0/5).
Key numbers: 5-year revenue growth of 248% a year, a 5-year average ROIC of -54%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 890% above the current price.
About Sunshine Biopharma
Sunshine Biopharma is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $1708 in 2015 to $36M in 2025, growth of about 170.9% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 51853% over three years (dilution for shareholders). It spends 2% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- Price below intrinsic value (DCF, moderate assumptions)
- 3-year revenue growth above 10% a year
- Profit margin improving
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35M | $36M | $35M | $24M | $4M | $228426 | $71410 | $21121 | $0 | $0 | $0 |
| Net income | -$6M | -$6M | -$5M | -$5M | -$27M | -$12M | -$3M | -$2M | -$2M | -$1M | -$3M |
| Free cash flow | — | -$6M | -$14M | -$9M | -$5M | -$2M | -$658490 | -$496658 | -$531656 | -$547238 | -$317621 |
| EPS (diluted) | $-7.42 | $-7.20 | $-36.60 | $-1756.80 | $-16695.58 | $-45153.95 | $-25897.12 | $-1422.92 | $-6735.15 | $-189.72 | $-94.86 |
| Net margin | -17.5% | -16.5% | -14.7% | -18.7% | -615.4% | -5444.4% | -3898.7% | -7860.9% | — | — | — |
| ROIC | — | -20.6% | -22.7% | -17.3% | -95.3% | -115.6% | -55.9% | — | -140.7% | -2917.1% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $1120.00, 41381% above the current price; targets range from $1120.00 to $1120.00; the consensus rating is “none”; expected EPS is $-39.00 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Sunshine Biopharma stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 890% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Sunshine Biopharma pay a dividend?
Not currently.
Is Sunshine Biopharma a good stock to buy?
We do not give buy or sell advice. Sunshine Biopharma scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.